The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a significant shift in the nation's healthcare management. The restructuring aims to cut bureaucracy and enhance efficiency, resulting in approximately 10,000 job losses, with the anticipated savings redirected to frontline services.
Health secretary Wes Streeting stated that the move would streamline operations, improve accountability, and ensure more effective resource utilization to address issues such as long waiting times.
The restructuring is expected to have significant implications for the pharmaceutical and biotech sectors. The government has indicated that centralizing NHS functions under direct control will enhance its ability to negotiate drug pricing and accelerate the adoption of new treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze